GenSight Biologics closes €32 million in financing for gene therapy

GenSight Biologics has raised €32 million in series A financing to help fund development of a gene replacement therapy for Leber’s hereditary optic neuropathy and an optogenetic therapy for retinitis pigmentosa, according to a company news release.GenSight will make use of its access to intellectual property from Novartis, along with a proprietary approach to targeting mitochondria development in Leber’s hereditary optic neuropathy.

Full Story →